TD Cowen reissued a hold rating on Crinetics Pharmaceuticals.
1 report, 1 independent
Updated Jul 9
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
TD Cowen reissued a hold rating on Crinetics Pharmaceuticals.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
TD Cowen
American investment bank
-
Crinetics Pharmaceuticals
company in San Diego, United States
Nothing else this week.
Related events
- TD Cowen reaffirmed a buy rating on Tectonic Therapeutic (TECX) on October 13, 2026.
- TD Cowen maintained and revised ratings and price targets for several fintech companies including Klarna, SoFi, Sezzle, Capital One, and Affirm.
- TD Cowen raised its price target for HCA Healthcare, Inc. on October 23, 2026.
- Bio-Techne shares traded on Nasdaq, and TD Cowen reiterated a Buy rating with a $65 price target.
- TD Cowen raised its price target for Celcuity Inc., which saw a stock price increase driven by a bullish rating.